2seventy bio, Inc.
TSVT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $38 | $100 | $91 | $55 |
| % Growth | -62.3% | 9.7% | 67.8% | – |
| Cost of Goods Sold | $23 | $17 | $26 | $13 |
| Gross Profit | $15 | $83 | $65 | $42 |
| % Margin | 40.4% | 83.1% | 71.3% | 76.9% |
| R&D Expenses | $77 | $231 | $249 | $262 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $44 | $69 | $79 | $94 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $10 | $21 | $0 | $0 |
| Operating Expenses | $131 | $321 | $328 | $355 |
| Operating Income | -$115 | -$238 | -$263 | -$314 |
| % Margin | -304.9% | -236.7% | -287.3% | -575% |
| Other Income/Exp. Net | $58 | $20 | $9 | $21 |
| Pre-Tax Income | -$57 | -$218 | -$254 | -$292 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$57 | -$218 | -$254 | -$276 |
| % Margin | -151.2% | -216.7% | -277.8% | -506.6% |
| EPS | -1.1 | -4.42 | -7.13 | -11.71 |
| % Growth | 75.1% | 38% | 39.1% | – |
| EPS Diluted | -1.1 | -4.42 | -7.13 | -11.71 |
| Weighted Avg Shares Out | 52 | 49 | 36 | 24 |
| Weighted Avg Shares Out Dil | 52 | 49 | 36 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $12 | $3 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $7 | $10 | $12 | $16 |
| EBITDA | -$98 | -$206 | -$251 | -$297 |
| % Margin | -260% | -205.6% | -274.7% | -545% |